Dr Reddy's buys UCB portfolio in S Asia
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories has snapped up a select portfolio of UCB's established products business in India, Nepal, Sri Lanka and Maldives for INR8bn ($128m), bolstering its presence in the high growth dermatology, respiratory and paediatric segments.
You may also be interested in...
Flurry Of Marketing Collaborations Set India Deal Street Abuzz
In-licensing and co-marketing/co-promotion deals are on the up in India, as local and foreign companies tango together to reach more patients and expand their business in the country's competitive market. Lupin-Boehringer, Dr Reddy’s-UCB and Glenmark-Helsinn are among the recent companies doing deals in the area.
M&A Trends: Private Equity And 'Aspirational' Execs Pair Up In India
Private equity firms partnering with senior management professionals bitten by the entrepreneurial bug to buy pharmaceutical businesses in India were some of the emerging trends highlighted by experts at a recent CPhI congress in Mumbai. Scrip covers the key conference highlights on the "maturing" Indian M&A market, including how foreign firms are shedding their older portfolios to reallocate resources to newer products.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.